[1] |
吕晓梅,陈涛,张小强,等.血清 HE4,CA125,CA199,CA724联合检测对卵巢癌早期诊断的临床价值探讨[J].国际检验医学杂志,2016,38(9):83.
|
[2] |
Amal Z,Azzam·Doaa I,Hashad·Nahla A,et al.Evaluation of HE4 as an extrabiomarker to improve detection of ovarian carcinoma:is it time for a step forward?[J].Arch Gynecol Obstet,2013,288(1):167-172.
|
[3] |
高磊,刘晓霞,王泳心,等.血清糖类抗原125和人附睾蛋白4联合检测在卵巢癌诊断中的价值[J].中国老年学杂志,2016,36(12):2958-2959.
|
[4] |
Siegel R,Naishadham D,Jemal A.Cancer statistics,2012[J].CA Cancer J Clin,2012,62(1):10-29.
|
[5] |
孙洁.CA199、CA125及HE4在卵巢癌中的检测意义[J].中国实验诊断学,2016,20(7):91-93.
|
[6] |
龚红霞,徐明娟.联合检测 HE4、CA125、CA19-9 和 CEA在卵巢癌诊断中的应用[J].中国医学前沿杂志(电子版),2015,7(10):41-44.
|
[7] |
Karlsen MA,Hogdall EVS,Christensen IJ,et al.A novel diagnostic index combining HE4,CA125 and age may improve triage of women with suspected ovarian cancer-an international multicenter study in women with an ovarian mass[J].Gynecol Oncol,2015,138(3):640-646.
|
[8] |
唐丽媛,谢力,王晓囡,等.血清 HE4,CA125 和 CA199 检测在卵巢肿瘤诊断中的临床意义[J].中国妇幼保健,2015,30(15):2352-2353.
|
[9] |
Kondalsamy-Chennakesavan S,Hackethal A,Bowtell D,et al.Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4,CA125,and CEA and patient′s age[J].Gynecol Oncol,2013,129(5):467-471.
|
[10] |
贾素娟,王治洁,张美琴,等.血清 HE4,CA125 和影像学检查在上皮性卵巢癌术后复发诊断中的应用价值[J].中国癌症杂志,2015,25(6):452-456.
|
[11] |
Sandri MT,Bottari F,Franchi D,et al.Comparison of HE4,CA125 and ROMA algorithm in women with a pelvic mass:correlation with pathological outcome[J].Gynecol Oncol,2013,128 (2):233-238.
|
[12] |
朱振宇,魏娜,严妮子.HE4联合CA125在卵巢癌早期诊断中的应用价值[J].现代肿瘤医学,2014,22(3):623-624.
|
[13] |
郝艳梅,郝亚飞.血清HE4和CA125联检对卵巢癌的诊断价值[J].国际检验医学杂志,2017,38(7):981-983.
|
[14] |
Romagnolo C,Leon AE,Fabricio ASC,et al.HE4,CA125 andriskofovarianmalignancyalgorithm(ROMA)asdiagnostic tools for ovarian cancer in patients with a pelvic mass:an Italian multicenter study[J].Gynecol Oncol,2016,141(2):303-311.
|
[15] |
胥琳璟,郑晓霞,王斌,等.血清 HE4、CA125 联合 TVCDS 诊断早期卵巢癌的应用分[J].河北医药,2017,39(5):668-670.
|